Pentraxin 3 in patients with type 2 diabetes and nonalcoholic fatty liver disease: a promising treatment target for glucagon-like peptide-1 receptor agonists. Authors' reply
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.